CoChat

GLP-1 receptor agonists: A clinical perspective on cardiovascular effects

Open access
Mundil, Dhanwantee, Cameron-Vendrig, Alison, Husain, Mansoor · 2012 · Diabetes and Vascular Disease Research

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Abstract

The active incretin hormone glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-amino acid peptide that exerts glucoregulatory and insulinotropic actions by functioning as an agonist for the GLP-1 receptor (GLP-1R). In addition to its anti-diabetic effects, GLP-1 has demonstrated cardioprotective actions. Here we review the cardiovascular effects of the GLP-1 analogues currently approved for the treatment of type 2 diabetes, namely exenatide and liraglutide. We discuss their anti-hyperglycaemic efficacy, and offer a clinical perspective of their effects on cardiovascular risk factors such as body weight, blood pressure, heart rate and lipid profiles, as well as their potential consequences on cardiovascular events, such as arrhythmias, heart failure, myocardial infarction and death. Lastly, we briefly review additional GLP-1R agonists in clinical development.

Overview

Integrity signals

Registry

Crossref · 10.1177/1479164112441526

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 88 references

Research works printed but not linked: 7

  1. Raufman JP, 1982, Am J Physiol, 242, G470
  2. Steensgaard DB, 2008, Diabetes, 57, A164
  3. Bjørnsdottir I, 2008, Diabetologia, 51, S356
  4. Wintle M, 2011, Diabetologia, 54, S1
  5. Plutzky J, 2009, Diabetologia, 52, S299, 10.1007/s00125-008-1193-7 · DOI
  6. Best JH, 2011, Diabetologia, 54, S1
  7. Administration USFaD, 2008, Guidance for industry diabetes mellitus

Cited by

See all 106

Metadata

Authors
Mundil, D., Cameron-Vendrig, A., & Husain, M.
Affiliations
University of Toronto (CA)
Venue
Diabetes and Vascular Disease Research
Published
2012-04
Volume
9
Issue
2
Pages
95-108
ISSN
  • 1479-1641 (ISSN-L)
  • 1752-8984
OpenAlex
W2092434810
Cited by
104
References
88
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2022: 3 · 2021: 13 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 8 · 2014: 25 · 2013: 20 · 2012: 2
FWCI
14.09
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Diabetes and Vascular Disease Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, glucagon-like peptide-1, exenatide, liraglutide, type 2 diabetes, cardiovascular safety, cardioprotection, blood pressure, heart rate, lipid profile, body weight, cardiac arrhythmias, heart failure, myocardial infarction
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Peptides, Risk Factors, Time Factors, Venoms, Drug Design, Biomarkers, Treatment Outcome, Receptors, Glucagon, Risk Assessment, Evidence-Based Medicine, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. https://app.cochat.ai/papers/10.1177/1479164112441526
The paper
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012). GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. Diabetes and Vascular Disease Research. https://doi.org/10.1177/1479164112441526

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.